CEO & CSO
Viktoria Enkmann
Leads RNA analytics, product strategy, customer discovery, scientific positioning and fundraising.
RNA/LNP analyticsProduct strategyCustomer discoveryFundraising
Company & Investors
Building the operating system for RNA analytical development.
RNAnalytics combines orderable analytical toolkits with a modality-aware software platform that turns fragmented laboratory outputs into governed development evidence.
Vision
Fix analytics. Unlock therapies.
RNA and advanced-therapy teams need scientific software that understands modality, preserves provenance and connects evidence across the program—not another disconnected calculation tool.
Physical foundation
GeneVectoAnalyzer standardizes high-value measurements on existing lab infrastructure.
Digital intelligence
RNAOS connects planning, analysis, quality, reporting and cross-program evidence.
Leadership team
Scientific depth, operations and regulated-software execution.
COO & CFO
Hannes-Oliver Burgstaller
Leads finance, operations, delivery systems, partnerships and scalable commercial execution.
OperationsFinanceUnit economicsScaling
CTO
Natalija
Leads software architecture, platform implementation, security and compliance-by-design.
Software architectureData modelsComplianceProgram delivery
Investor overview
A focused market entry into a broad RNA analytics platform opportunity.
GeneVectoAnalyzer creates a tangible entry point in the laboratory. RNAOS compounds value through recurring workflows, subscriptions, credits, enterprise integration and an accumulating canonical evidence layer.
1
Land
Orderable toolkits and one governed analytical workflow solve an immediate, measurable customer problem.
2
Expand
Additional assays, planning, quality, stability, comparability and reporting expand across teams and programs.
3
Compound
Canonical records and cross-assay intelligence become a differentiated data asset and increase switching costs.
Toolkits + SaaSConsumables drive adoption; software scales margin and retention.
Regulated workflowsGovernance infrastructure supports premium enterprise deployments.
Multi-modalityRNA, LNP, oligos, viral vectors and adjacent ATMP programs.
Customer pilotsClear success criteria create a practical path from pilot to wider deployment.
Investor materials
See what is built and how the platform expands.
Full investor materials, commercial packaging and technical evidence are available by request.